Accessibility Menu
Aequus Pharmaceuticals logo

Aequus Pharmaceuticals(OTC) AQSZF

Market Cap$159.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-99%
1 Year-66%
1 Month-54%
$0.00
+0.00%
+0.00Today
Aequus Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-20
Aequus Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-13
1 month-53.85%USD 0.002026-07-14
3 month+9.09%USD 0.002026-05-22
Year to date-40%USD 0.002025-12-22
1 year-65.71%USD 0.002025-08-20
3 year-96.39%USD 0.032023-08-15
5 year-98.94%USD 0.112021-08-20
Since inception-99.71%USD 0.412015-06-16

Aequus Pharmaceuticals Financials at a Glance

Market Cap

$159.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$918.47K

Net Income (TTM)

-CA$656.34K

EPS (TTM)

-$0.00

P/E Ratio

-0.35

Dividend

$0.00

Beta (Volatility)

-6.65 (Low)

Price

$0.00

Volume

102,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Aug 20, 2026

AQSZF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aequus Pharmaceuticals

Aequus Pharmaceuticals Inc. is a specialized pharmaceutical firm based in Vancouver, Canada, focused on developing and commercializing medicinal products. The company targets key medical disciplines, including neurological conditions, ophthalmology, and transplantation medicine.

Products and Services
  • Vistitan, an ophthalmic solution for glaucoma and ocular hypertension
  • Tacrolimus IR, an immunosuppressive drug for organ transplant management
  • The Evolve range of dry eye products for symptom relief
Growth Outlook
  • Recent quarterly revenue increased to CAD 251,754, showing positive momentum
  • Strategic alliances with industry leaders enhance market reach and product visibility
  • Development pipeline includes innovative therapies for epilepsy and nausea during pregnancy
Financial Highlights
  • Trailing twelve months (TTM) revenue of CAD 918,000 reflects growth potential
  • Net income for Q3 2025 was CAD 370,483, indicating operational improvements
  • Gross profit margin improved to 52.5% in Q3 2025, showcasing effective cost management
Aequus Pharmaceuticals Inc. is positioned in the healthcare sector, specifically within the drug manufacturing industry. The company has a diverse product portfolio that addresses significant medical needs, particularly in ophthalmology and transplantation. Recent financial performance indicates a positive trend, with increasing revenues and improved gross profit margins. The strategic partnerships with established pharmaceutical companies further bolster Aequus's market presence and potential for growth. The ongoing development of innovative therapies in the pipeline suggests a commitment to expanding its offerings and addressing unmet medical needs. Overall, Aequus Pharmaceuticals presents an intriguing opportunity for investors interested in the pharmaceutical sector.
AI Generated • Aug 20, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

15

CEO

Douglas Glen Janzen

Website

www.aequuspharma.ca

Headquarters

Vancouver, BC V6C 1S4, CA

AQSZF Financials

Key Financial Metrics (TTM)

Gross Margin

53.98%

Operating Margin

-38.34%

Net Income Margin

-62.96%

Return on Equity

6.18%

Return on Capital

-1350.65%

Return on Assets

-223.56%

Earnings Yield

-2.86%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$159.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

132.63M

Volume

102.00K

Avg. Volume

8.98K

Financials (TTM)

Gross Profit

CA$523.04K

Operating Income

-CA$574.04K

EBITDA

-CA$348.26K

Operating Cash Flow

-CA$115.84K

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$115.84K

Cash & ST Invst.

CA$9.95K

Total Debt

CA$4.33M

Aequus Pharmaceuticals Performance Analysis

Aequus Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31CAD 2,165,293N/A
20222022-12-31CAD 1,059,852-51.1%
20232023-12-31CAD 188,856-82.2%
20242024-12-31CAD 426,462125.8%
Aequus Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3149.6%
Q12025-03-312.1%
Q22025-06-30-3.7%
Q32025-09-3015.4%
Aequus Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31CAD -0.01N/A
20222022-12-31CAD -0.0266.1%
20232023-12-31CAD -0.02-10.8%
20242024-12-31CAD -0.01-27.7%
Aequus Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3165.2%
Q12025-03-31-206.3%
Q22025-06-3075.5%
Q32025-09-30333.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

CA$251.75K

+69.7%

Gross Profit

CA$132.07K

+75.1%

Gross Margin

52.46%

N/A

Market Cap

$159.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$13.27K

N/A

Employees

12

N/A

Net Income

CA$370.48K

+160.3%

EBITDA

CA$308.31K

+160.0%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

CA$9.95K

-60.8%

Total Debt

CA$4.33M

-33.8%

Accounts Receivable

CA$165.75K

+154.1%

Inventory

CA$3.54K

-96.4%

Long Term Debt

CA$0.00

-100.0%

Short Term Debt

CA$4.33M

-28.4%

Return on Assets

-2.24%

N/A

Return on Invested Capital

3.87%

N/A

Free Cash Flow

-CA$21.22K

+93.9%

Operating Cash Flow

-CA$21.22K

+93.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HPMMHemp Naturals, Inc.
$0.00+0.00%
DVLPGolden Developing Solutions, Inc.
$0.00+0.00%
TOMDFTodos Medical Ltd.
$0.00+0.00%
BIOAFBioasis Technologies Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About AQSZF

What is the current price of Aequus Pharmaceuticals?

Aequus Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Aequus Pharmaceuticals?

Over the past 52 weeks, Aequus Pharmaceuticals has traded between $0.00 and $0.01.

How much debt does Aequus Pharmaceuticals have?

As of the most recent reporting period, Aequus Pharmaceuticals reported total debt of CA$4.33M.

How much cash does Aequus Pharmaceuticals have on hand?

Aequus Pharmaceuticals reported CA$9.96K in cash and cash equivalents in its most recent financial results.

What is Aequus Pharmaceuticals’s dividend yield?

Aequus Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services